Phase 2 N=18 Intravenous Allopurinol in Heart Failure
Congestive Heart Failure
Primary: Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion — 2.07 umol/g/sec
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=89 Efficacy and Safety Study of ESBA1008 Versus EYLEA®
Exudative Age-Related Macular Degeneration
Primary: Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12 — 54.1; 55.6; 5.8; 6.9 letters
Phase 2 N=74 Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Metastatic Colorectal Cancer
Primary: PFS Hazard Ratio — 0.365 months — p=0.0130
Phase 2 N=36 Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Phase 2 N=8 Sodium Oxybate in Schizophrenia With Insomnia
Schizophrenia · Insomnia Related to Schizophrenia (307.42)
Primary: Pittsburgh Sleep Quality Index — 6.1 global score — p==0.002
Phase 2 N=142 Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Unresectable Melanoma · Metastatic Melanoma
Primary: Objective Response Rate (ORR) - BRAF Wild-type (WT) Participants — 60.3; 10.8 Percentage of participants
Phase 2 N=90 Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020
Phase 2 N=61 Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients
Asthma
Primary: Baseline-Adjusted Area-Under-The-Percent-Predicted Forced Expiratory Volume In 1 Second (FEV1) Versus Time Curve Over 6 Hours Post-Dose — 46.6; 48.0; 37.9; 49.1…
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=30 Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Cystic Fibrosis
Primary: Adverse Events — 100; 80; 60 percentage of participants
Phase 2 N=24 N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults
HIV · Endothelial Dysfunction · Oxidative Stress
Primary: Change in Circulating Malondialdehyde Levels — 0.17; -0.12; -0.00 micromolar
Phase 2 N=36 Safety of SonoVue on Pulmonary Hemodynamics
Pulmonary Hypertension
Primary: Effects of SonoVue and Placebo on Pulmonary Hemodynamics: Systolic Pulmonary Artery Pressure (mmHg) - Mean Change From Baseline — 50.50; 50.50; 30.08; 30.08 mmHg
Phase 2 N=616 Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
Asthma
Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 2.40; 1.24; 1.46; 1.15 Exacerbations per year — p=<0.001
Phase 2 N=28 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Response — 0 percentage of participants
Phase 2 N=35 RAD001 in Recurrent Endometrial Cancer Patients
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants